Pharmaceutical companies AstraZeneca and Generic Health have laid down their swords in a long-running patent dispute over AstraZeneca’s cholesterol drug Crestor, two-and-a-half years after the High Court of Australia found the patent obvious and invalid.
Subscribe for instant access to all Lawyerly content.
